WallachAIWaltzMCasperTC, et al. Cognitive processing speed in pediatric-onset multiple sclerosis: Baseline characteristics of impairment and prediction of decline. Mult Scler. Epub ahead of print 28November2019. DOI: 10.1177/1352458519891984.
2.
HalperJ. The psychosocial effect of multiple sclerosis: The impact of relapses. J Neurol Sci2007; 256: S34–S38.
3.
ChitnisTArnoldDLBanwellB, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med2018; 379(11): 1017–1027.
4.
KruppLBanwellBChitnisT, et al. The Effect of Fingolimod on Quality of Life in paediatric patients with MS: Results of the Phase 3 PARADIGM Study. Mult Scler J2018; 24: 518.
5.
WaubantEBanwellBWassmerE, et al. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology2019; 92(22): e2538–e2549.
6.
SchmidliHHäringDAThomasM, et al. Beyond randomized clinical trials: Use of external controls. Clin Pharmacol Ther2020; 107: 806–816.
7.
HardingKWilliamsOWillisM, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol2019; 76(5): 536–541.
8.
KryskoKMGravesJSRenselM, et al. Real-world effectiveness of initial disease-modifying therapies in pediatric MS. Ann Neurol. Epub ahead of print 8April2020. DOI: 10.1002/ana.25737.
9.
YamamuraTKleiterIFujiharaK, et al. Trial of satralizumab in neuromyelitis optica Spectrum disorder. N Engl J Med2019; 381(22): 2114–2124.
10.
BaulacMRosenowFToledoM, et al. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: A phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol2017; 16(1): 43–54.
